[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350454-105":59,"doc-detail-350454-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-uptake-of-gbrca-testing-as-a-companion-diagnostic-for-olaparib-in-patients-with-high-risk-her2-negative-early-breast-cancer-in-japan-a-cross-sectional-multicenter-study-brcawareness","Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan - a cross-sectional multicenter study (BRCAwareness)","","Adjuvant olaparib improves outcomes for high-risk HER2-negative, early breast cancer patients with germline BRCA1/2 pathogenic variants, making timely gBRCA companion diagnostic testing essential. This cross-sectional multicenter study enrolled patients undergoing curative surgery in Japan in 2023, using OlympiA criteria to define eligibility. Among 691 analyzed patients, the gBRCA testing rate was 63.2%. Untested patients were often uninformed due to physician oversight, with additional reasons including psychological distress and testing cost.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-uptake-of-gbrca-testing-as-a-companion-diagnostic-for-olaparib-in-patients-with-high-risk-her2-negative-early-breast-cancer-in-japan-a-cross-sectional-multicenter-study-brcawareness/350454/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-uptake-of-gbrca-testing-as-a-companion-diagnostic-for-olaparib-in-patients-with-high-risk-her2-negative-early-breast-cancer-in-japan-a-cross-sectional-multicenter-study-brcawareness/350454.png","ImageObject",300,407,{"name":92,"@type":93},"Mimi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main outcome of the study?","Question",{"text":112,"@type":113},"The primary outcome was the gBRCA testing rate among eligible patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why did many patients remain untested?",{"text":117,"@type":113},"Among untested patients, the largest share were not informed, mainly due to physician oversight in recognizing eligibility or physician-perceived ineligibility.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were associated with lower gBRCA testing rates?",{"text":121,"@type":113},"Multivariable analysis (female only) found that age ≥65, postmenopausal status, major comorbidities, upfront surgery, absence of family history of HBOC-related cancers, and absence of bilateral or multiple primary breast cancers were associated with lower testing rates.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350454,1790167802,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Breast Cancer (2026) 33:919–927  \n[https://doi.org/10.1007/s12282-026-01867-y](https://doi.org/10.1007/s12282-026-01867-y)  \nORIGINAL ARTICLE  \nReal-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness)  \nTomoeTaji1 · Yukari Uemura2 · Yuri Kimura3 · Noriko Maeda4 · Aki Ito5 · Hirohito Seki6 · Daisuke Takabatake7 · Michiko Harao8 · Shogo Nakamoto9 · Ryoichi Matsunuma10 · Chinatsu Koganezawa11 · Takayuki Iwamoto12 · Hirofumi Mukai13 · Yuichiro Kikawa1  \nReceived: 24 March 2026 / Accepted: 8 May 2026 / Published online: 23 May 2026 © The Author(s) 2026  \nAbstract  \nBackground Adjuvant olaparib significantly improves invasive disease-free and overall survival in high-risk human epidermal growth factor receptor 2 (HER2)-negative, early breast cancer patients carrying germline breast cancer susceptibility gene 1/2 (gBRCA) pathogenic variants (PVs) . Timely gBRCA testing as a companion diagnostic for adjuvant olaparib is essential. However, its real-world uptake remains unclear.  \nMethods We enrolled patients with invasive HER2-negative early breast cancer who underwent curative surgery during 2023 in Japan. Eligibility was based on the OlympiA trial criteria. Estrogen receptor (ER)-positive patients required ≥ 4 positive nodes after surgery or non-pathological complete response (non-pCR) with clinical and pathologic stage (CPS) and estrogen receptor status and histologic grade (EG) score ≥ 3 following neoadjuvant chemotherapy (NAC) . ER-negative patients required invasive tumor >2 cm or ≥ 1 nodal metastasis after surgery, or non-pCR after NAC. The primary outcome was gBRCA testing rate; secondary outcomes included a proportion of patients with gBRCA PVs and a proportion of patients starting adjuvant olaparib. We also explored factors associated with not undergoing testing.  \nResults Of 824 patients enrolled from 46 facilities, 691 were analyzed after random sampling and exclusions. The testing rate was 63.2%(95% confidence interval 59.5–66.9). Among 254 untested patients, 168 (66%) were not informed—mainly due to physician oversight in recognizing eligibility (57%) or physician-perceived patient ineligibility (40%) . Of 69 informed but untested patients, reasons included psychological distress (46%), testing cost (35%), and familial concerns (12%) . Of 42 patients (9.6%) with gBRCA PVs, 32 received olaparib. Multivariable analysis (female only) showed that age ≥ 65 years, postmenopausal status, major comorbidities, upfront surgery, absence of family history of hereditary breast and ovarian cancer-related cancers, and absence of bilateral or multiple primary breast cancers were associated with lower testing rates. Conclusion Greater physician awareness of companion diagnostic is needed to ensure timely gBRCA testing and equitable access to adjuvant olaparib.  \nKeywords BRCA · Olaparib · High-risk early breast cancer  \nIntroduction  \nThe number of breast cancer patients in Japan has been gradually increasing, with 101,793 new cases diagnosed among Japanese women in 2022 [1] . Hereditary breast and ovarian cancer (HBOC) is the most common cancer predisposition syndrome associated with breast cancer, caused by  \npathogenic variants (PVs) in germline BRCA1 /2 (gBRCA)  \n[2] . A diagnosis of HBOC enables the implementation of risk-reducing strategies, including intensified surveillance, chemoprevention, and risk-reducing surgery.  \nPoly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated clinical benefit in patients with breast cancer carrying gBRCA PVs. In particular, the phase III OlympiA  \nExtended author information available on the last page of the article  \ntrial showed that adjuvant olaparib significantly improved invasive disease-free survival (IDFS) and overall survival (OS) in high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients with gBRCAPVs [3","cbCaij04L2ErToQu","https://ap.wps.com/l/cbCaij04L2ErToQu","pdf",1155746,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Rationale and need for real-world data\n# Patients and methods\n## Study design and eligibility criteria","[{\"question\":\"What was the main outcome of the study?\",\"answer\":\"The primary outcome was the gBRCA testing rate among eligible patients.\"},{\"question\":\"Why did many patients remain untested?\",\"answer\":\"Among untested patients, the largest share were not informed, mainly due to physician oversight in recognizing eligibility or physician-perceived ineligibility.\"},{\"question\":\"Which factors were associated with lower gBRCA testing rates?\",\"answer\":\"Multivariable analysis (female only) found that age ≥65, postmenopausal status, major comorbidities, upfront surgery, absence of family history of HBOC-related cancers, and absence of bilateral or multiple primary breast cancers were associated with lower testing rates.\"}]","Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan - a cross-sectional multicenter study (BRCAwareness) | PDF",1790089123,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cca12e2a567e4601bcc2e1214e1bd3df.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e6f73f166ca19b1034b5a853e6a1763.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8ef88409d91bf8d980d0ea0d3646bde.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5c7072e07f391d57332852229593c34.webp",980,1301]